Vancomycin loading dose individualization in a population of obese patients undergoing haemodialysis based on population pharmacokinetic model
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61383082%3A_____%2F24%3A00001375" target="_blank" >RIV/61383082:_____/24:00001375 - isvavai.cz</a>
Result on the web
<a href="https://pubmed.ncbi.nlm.nih.gov/38887026/" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/38887026/</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/1120009X.2024.2367937" target="_blank" >10.1080/1120009X.2024.2367937</a>
Alternative languages
Result language
angličtina
Original language name
Vancomycin loading dose individualization in a population of obese patients undergoing haemodialysis based on population pharmacokinetic model
Original language description
This study aimed to develop a vancomycin population pharmacokinetic model in obese adult patients treated with intermittent haemodialysis and propose a model-based loading dose strategy ensuring attainment of newly recommended AUC-based PK/PD target. Retrospective cross-sectional analysis was performed among obese haemodialysis dependent adult patients treated with intravenous vancomycin. A pharmacokinetic population model was developed using a nonlinear mixed-effects modelling approach and Monte Carlo simulations were used to identify the optimal loading dose for PK/PD target attainment during the first 48 h of treatment. Therapeutic drug monitoring data from 27 patients with a BMI of 30.2–52.9 kg/m2 were analysed. Among all tested variables, only LBM as a covariate of vancomycin Vd significantly improved the model, while vancomycin CL did not correlate with any of the tested variables. The median (IQR) value from the conditional mean of individual estimates of Vd and CL was 68.4 (56.6–84.2) L and 0.86 (0.79–0.90) L/h, respectively. To ensure optimal vancomycin exposure during the first 48 h of therapy, the vancomycin loading dose of 1500, 1750, 2000, 2250, 2500 and 2750 mg should be administered to obese patients with a lean body mass of ˂50, 50–60, 60–70, 70–80, 80–85 and >85 kg, respectively.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of chemotherapy
ISSN
1120-009X
e-ISSN
—
Volume of the periodical
2024
Issue of the periodical within the volume
Jun 17
Country of publishing house
IT - ITALY
Number of pages
10
Pages from-to
1-10
UT code for WoS article
001250717600001
EID of the result in the Scopus database
2-s2.0-85196285368